MedChem Australia's mission is to work with the Australian biomedical research and biotech community to develop new medicines through creativity and collaboration. MedChem Australia will provide expert medicinal chemistry & DMPK capability plus drug discovery mentorship at subsidised cost to enhance, accelerate, and enable the development of new small molecule therapeutics. Projects to receive subsidised support will be selected through a competitive and independent application process. Projects should be innovative, address an unmet medical need, and contain existing chemistry. 

MedChem Australia will have an annual call for applications, with Australian Universities, Medical Research Institutes, and SMEs eligible to apply. Discussion of applications with MedChem Australia prior to submission is encouraged. Further information on how to apply and engage with MedChem Australia is available on our website. 

MedChem Australia brings together three of the nation’s top medicinal chemistry groups from Monash University, WEHI and the University of Sydney, each with a track record of success in commercially-focused drug discovery. Projects will be allocated to one of these three MedChem Australia Nodes where MedChem Australia scientists will help plan the chemistry strategy for the project, design compounds, make compounds, generate in vitro & in vivo DMPK data, and drive the project forward. 

MedChem Australia was established with $15 million in funding from the Federal Government’s Medical Research Future Fund, Therapeutic Innovation Australia (TIA) and the three nodes, with an initial runway of 5 years. 

Please follow MedChem Australia and stay tuned for updates regarding this exciting initiative.

MedChem Australia

Org chart

Teams

Offices